Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.
Pharmaceutical Executive July 1, 2009	The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.
Pharmaceutical Executive October 1, 2011	Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy.
Pharmaceutical Executive June 9, 2014 Kleinrock & Noor	Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.
Pharmaceutical Executive August 1, 2013 Joseph Saba	New Rules for a New Africa Declining revenue growth in the United States and Europe have sent pharmaceutical companies in search of opportunities in the BRICs and other emerging economies. Now, companies are finally turning their attention to Africa.
Pharmaceutical Executive March 12, 2012 William Looney	Novartis: LEADing in Emerging Markets With growth as its guiding light, Novartis has big plans for the emerging markets. CEO Joe Jimenez tells us what it will take the company to best the competition.
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Finance & Development September 2010	Regaining Momentum Progress on the Millennium Development Goals has been slowed by the crisis. The rest of the world has to help.
Finance & Development March 2011 Clements et al.	Healing Health Care Finances Health care presents a daunting fiscal challenge in advanced and emerging economies alike, but reforms can help manage the growth of spending fairly and efficiently.
Pharmaceutical Executive January 1, 2012 William Looney	Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
Chemistry World July 16, 2012 Andrew Turley	Drug spending to hit $1.2tn in 2016 Global expenditure on medicines will top $1.2 trillion in 2016, up from $960 billion in 2011, according to a report from the IMS Institute for Healthcare Informatics.
Pharmaceutical Executive May 1, 2012	Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory.
Finance & Development June 2011	Emerging Challenges Emerging markets must adapt to the new global reality by building on their economic success.
Pharmaceutical Executive June 9, 2014 Genenz et al.	Surviving the Price Wars in Emerging Markets: Three Myths and Three Lessons How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment.
Finance & Development December 2011 Antoinette Sayeh	The Quality of Growth The questions that continually nag at me concern the quality of this growth in sub-Saharan Africa. In particular, is it inclusive -- are the poor and the young benefiting -- and is it sustainable?
Pharmaceutical Executive November 1, 2013	Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation.
Chemistry World June 5, 2009 Anna Lewcock	Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts.
Pharmaceutical Executive July 3, 2007	Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future.
Finance & Development September 1, 2006 Peter S. Heller	Asia: Ready or Not The world's most populous continent must prepare now for an aging population.
Pharmaceutical Executive May 1, 2011 Stan Bernard	Competition 2.0: Brands vs. Generics Innovator and generics companies are colliding as they invade each other's turf.
Pharmaceutical Executive August 1, 2012	Country Report: Mexico Jim O'Neill, chief economist at Goldman Sachs declared that by 2020 Mexico would be the seventh largest economy in the world, surpassing both India and Russia. The Mexican pharmaceutical industry has seen some significant changes over the last four years.
Food Processing October 2011 Dave Fusaro	China and India Are Hungry ... for Your Products Now, the two most populous countries also are the fastest-growing; their burgeoning middle classes are developing Western cravings.
Pharmaceutical Executive March 1, 2013	China and the Emerging Markets Challenge: Why Big Pharma Must Embrace a New Strategy With health reform already tagged as a key domestic priority, their policies will pose new opportunities and challenges for Big Pharma companies active in China.
Registered Rep. May 10, 2012 Jennifer Duell Popovec	Emerging Real Estate in Emerging Markets While most investors lack a deep understanding of emerging markets overall, most of them know enough to be excited about these countries and the investment opportunities they offer.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Finance & Development December 2010	Emerging Markets Come of Age These vibrant middle-income countries survived the global recession, but face bumps as they seek to solidify their place in the world economy.
IndustryWeek January 19, 2011	Growth in Emerging Economies Spells Opportunities Emerging markets offer vast opportunities for American manufacturers - both in exports and direct foreign investment.
Pharmaceutical Executive July 1, 2012	Country Report: Thailand Indochina's biggest pharmaceutical market has quickly matured over the past years due to the implementation of heavy cost containment measures meant to make healthcare more accessible to the patient.
Pharmaceutical Executive February 1, 2012	Brazil Report: A Bold Player Blooms Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now.
Pharmaceutical Executive February 1, 2011 Jon Zifferblat	China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country
Finance & Development December 1, 2005 Saavedra & Arias	Stuck in a Rut Avenues for combating persistent poverty and inequality in Latin America.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Pharmaceutical Executive January 21, 2014 William Looney	Russia's Bet on Biopharma Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector
Pharmaceutical Executive May 1, 2012	Government: Big Pharma's Best Friend in Emerging Markets? To gain market access in emerging markets, pharma companies face pressure to offer a convincing Corporate Value Proposition to governments.
CRM July 1, 2009 Dave Rich	New Routes to New Customers A customer-centric approach for emerging markets.
Finance & Development September 2010 Mark Horton	How Grim a Fiscal Future? For most advanced economies, both the near term and the longer term are tight, but there are ways to ease budget pressures
Bank Systems & Technology June 26, 2006 Maria Bruno-Britz	Lands of Opportunity The international opportunities for U.S. banks with the right IT and know-how can be huge, provided they follow the appropriate strategy.
The Motley Fool April 5, 2011 Frank Vinluan	GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep.
Pharmaceutical Executive January 1, 2009 Stan Bernard	Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms.
The Motley Fool January 22, 2009 Tim Hanson & Nate Weisshaar	Who Will Rebound First? Emerging market news: Emerging markets look more appealing than developed markets... China announces a $120 billion proposal to expand insurance coverage across China and increase access to health care in both rural and urban areas... etc.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
BusinessWeek April 15, 2010 Kanoko Matsuyama	Looking East, Big Pharma Cuts Prices Drugmakers are beginning to choose sales volume over high margins to tap the massive Asian market
Pharmaceutical Executive April 1, 2012	Leading from the South India's most prominent scientist sets a new agenda for pharma in emerging markets.
Pharmaceutical Executive August 1, 2008	Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how.
Pharmaceutical Executive July 1, 2011 Mangesh Sai	What the 2011 Census of India Reveals for Pharma What India's latest census tells us about current and future pharma opportunities.
Pharmaceutical Executive August 1, 2012 Debbie Warner	Adapting to a New Era of Cancer Care Coverage and treatment decisions will be driven by value and defined differently by each stakeholder.
Pharmaceutical Executive August 1, 2012 Carol Ann Williams	Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
Finance & Development December 1, 2007 David E. Bloom	Governing Global Health How better coordination can advance global health and improve value for money.